Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2995
Single User License Price INR 202013
Corporate User License Price USD 8985
Corporate User License Price INR 606038
Site License Price USD 5990
Site License Price INR 404026
Request a Quote

Report Title

HER2-Negative Breast Cancer - Current and Future Players

Quote Request for License Type
License Type Price  
Single User License USD 2995
Site License USD 5990
Enterprise Wide License USD 8985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

HER2-Negative Breast Cancer - Current and Future Players


Quote Request for License Type
License Type Price  
Single User License USD 2995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

HER2-Negative Breast Cancer - Current and Future Players

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

HER2-Negative Breast Cancer - Current and Future Players



Executive Summary

HER2-Negative Breast Cancer - Current and Future Players

Summary

GlobalData has released its pharma report, "HER2-Negative Breast Cancer - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Insomnia Market. The report identifies and analyses the key companies shaping and driving the global Insomnia market. The report provides insight into the competitive Insomnia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for HER2-Negative Breast Cancer

- Competitor assessment

- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

- Strategic assessment of HER2-Negative Breast Cancer sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving HER2-Negative Breast Cancer market

- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

- Create an effective counter-strategy to gain a competitive advantage against those currently in the market

- What's the next big thing in the global HER2-Negative Breast Cancer market landscape? Identify, understand and capitalize

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Catalyst 6

2.2 Related Reports 6

2.3 Upcoming Related Reports 7

3 Market Outlook 8

3.1 Global Markets 8

3.1.1 Forecast 8

3.1.2 Drivers and Barriers - Global Issues 14

4 Current and Future Players 16

4.1 Overview 16

4.2 Trends in Corporate Strategy 18

4.3 Company Profiles 21

4.3.1 AstraZeneca 21

4.3.2 Bristol-Myers Squibb 22

4.3.3 Eli Lilly 24

4.3.4 Pfizer 25

4.3.5 Novartis/GlaxoSmithKline 28

5 Appendix 30

5.1 Bibliography 30

5.2 Abbreviations 57

5.3 Methodology 65

5.4 Forecasting Methodology 65

5.4.1 Diagnosed HER2-Negative Breast Cancer Patients 65

5.4.2 Percentage of Drug-Treated Patients 66

5.4.3 Drugs Included in Each Therapeutic Class 66

5.4.4 Launch and Patent Expiry Dates 67

5.4.5 General Pricing Assumptions 68

5.4.6 Individual Drug Assumptions 70

5.4.7 Generic Erosion 78

5.4.8 Pricing of Pipeline Agents 78

5.5 Primary Research - KOLs Interviewed for This Report 89

5.6 Primary Research - High-Prescriber Survey 91

5.7 About the Authors 92

5.7.1 Analyst 92

5.7.2 Director of Oncology 92

5.7.3 Epidemiologist 93

5.7.4 Director of Epidemiology 93

5.7.5 Global Head of Healthcare 94

5.8 About GlobalData 95

5.9 Disclaimer 95

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Global Sales ($m) for HER2-Negative Breast Cancer by Region, 2013-2023 12

Figure 2: Global Sales for HER2-Negative Breast Cancer by Drug, 2013-2022 13

Figure 3: Global Sales ($m) of Branded Products for HER2-Negative Breast Cancer by Company*, 2013-2023 17

Figure 4: Company Portfolio Gap Analysis in HER2-Negative Breast Cancer 2013-2023 18

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for HER2-Negative Breast Cancer, 2013-2023 11

Table 2: Global HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023 14

Table 3: AstraZeneca's, Breast Cancer Portfolio Assessment, 2014 22

Table 4: AstraZeneca SWOT Analysis, 2014 22

Table 5: BMS' Breast Cancer Portfolio Assessment, 2014 24

Table 6: BMS SWOT Analysis, 2014 24

Table 7: Eli Lilly SWOT Analysis, 2014 25

Table 8: Pfizer's Breast Cancer Portfolio Assessment, 2014 27

Table 9: Pfizer SWOT Analysis, 2014 27

Table 10: Novartis' Breast Cancer Portfolio Assessment, 2014 29

Table 11: Novartis SWOT Analysis, 2014 29

Table 12: HER2-Negative Breast Cancer Incidence, 2013-2023 66

Table 13: Key Launch Dates of Marketed and Pipeline Drugs for HER2-Negative Breast Cancer 67

Table 14: Key Expiry Dates of Marketed and Pipeline Drugs Used in HER2-Negative Breast Cancer 68

Table 15: Average Body Weight and Surface Area Across the 8MM 69

Table 16: Cost per Treatment Cycle ($) - Abraxane, Metastatic Setting (HR+) 72

Table 17 Cost per Treatment Cycle ($) - Avastin, Metastatic Setting (HR+/TNBC) 73

Table 18: Cost per Treatment Cycle ($) - Afinitor, Third-Line Hormonal/ Targeted Therapy 74

Table 19: Cost per Treatment Cycle ($) - Doxil, Metastatic Setting (HR+/TNBC) 75

Table 20: Cost per Treatment Cycle ($) - Halaven, Metastatic Setting (HR+/TNBC) 76

Table 21: Cost per Treatment Cycle ($) - Ixempra, Metastatic Setting (HR+/TNBC) 77

Table 22 Cost per Treatment Cycle ($) - Xeloda, Metastatic Setting (HR+/TNBC) 78

Table 23: Cost per Treatment Cycle ($) - Abemaciclib, First-/Second-Line Hormonal/Targeted Metastatic Setting (HR+) 79

Table 24: Cost per Treatment Cycle ($) - Buparlisib, Postmenopausal Hormonal Neoadjuvant, Second- and Third-Line Hormonal/Targeted Metastatic Settings (HR+) 80

Table 25: Cost per Treatment Cycle ($) - Javlor, Third-Line Chemotherapy Metastatic Setting (HR+) 81

Table 26: Cost per Treatment Cycle ($) - LEE011, Postmenopausal Hormonal Neoadjuvan, and First-Line Hormonal/Targeted Metastatic Settings (HR+) 82

Table 27: Cost per Treatment Cycle ($) - NeuVax, Adjuvant Setting (HR+) 83

Table 28: Cost per Treatment Cycle ($) - Niraparib, Metastatic TNBC Setting 83

Table 29: Cost per Treatment Cycle ($) - NKTR-102, Third Line Chemotherapy Metastatic Setting (HR+) 84

Table 30: Cost per Treatment Cycle ($) - Lynparza, Adjuvant and First-Line Metastatic TNBC Settings 85

Table 31: Cost per Treatment Cycle ($) - Palbociclib, First- and Second-Line Hormonal/Targeted Metasatatic Setting (HR+) 86

Table 32: Cost per Treatment Cycle ($) - Talazoparib, Third-Line Metastatic TNBC Setting 87

Table 33: Cost per Treatment Cycle ($) - Veliparib, Neoadjuvant and Second-Line Metastatic TNBC Settings 88

Table 34: Physicians Surveyed by Country 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AstraZeneca

Bristol-Myers Squibb

Eli Lilly

Pfizer

Novartis/GlaxoSmithKline


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand